# Example: Comparing Clinical Studies

This example demonstrates how to use the `clinicaltrials_compare_studies` tool to perform a side-by-side comparison of two or more clinical trials.

## Example 1: Comparing Two Studies

### Tool Call

```json
{
  "nctIds": [
    "NCT04819100",
    "NCT06955377"
  ],
  "compareFields": "all"
}
```

### Tool Response

# Comparison of 2 Clinical Trials

## Studies
- **NCT04819100**: LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
- **NCT06955377**: Effect of Forward Trunk Flexion in Patients With Parkinson's Disease on the Airway Defense System

## Commonalities
- All studies are in phase: PHASE3
- Common countries: Czechia

## Key Differences
- Different lead sponsors: Eli Lilly and Company, General University Hospital, Prague
- Different statuses: ACTIVE_NOT_RECRUITING, RECRUITING

---

## Detailed Comparison

### NCT04819100: LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC

**Status:**
- Overall Status: ACTIVE_NOT_RECRUITING
- Start Date: 2021-12-20
- Completion Date: 2028-05

**Design:**
- Study Type: INTERVENTIONAL
- Phases: PHASE3
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Primary Purpose: TREATMENT
- Masking: TRIPLE

**Eligibility:**
- Sex: ALL
- Minimum Age: 18 Years
- Healthy Volunteers: false
- Age Groups: ADULT, OLDER_ADULT
- Criteria: Inclusion Criteria:

* Must have histologically confirmed Stage IB, II, or IIIA NSCLC.
* Must have an activating RET gene fusion in tumor based on polymerase chain reaction (PCR), next generation sequ...

**Interventions:**
- DRUG: Selpercatinib
  Administered orally.
- DRUG: Placebo
  Administered orally.

**Primary Outcomes:**
- Event-Free Survival (EFS)
  Time Frame: Randomization to disease recurrence/progression or death from any cause (estimated as up to 7 years)

**Secondary Outcomes:**
- EFS
- Overall Survival (OS)
- EFS
  ...and 5 more

**Sponsors:**
- Lead: Eli Lilly and Company (INDUSTRY)
- Collaborators: 1
  - Loxo Oncology, Inc.

**Locations:**
- Total: 211
- Countries: United States, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Greece, Hong Kong, India, Israel, Italy, Japan, Mexico, Netherlands, Norway, Poland, Puerto Rico, Romania, Russia, Singapore, South Korea, Spain, Sweden, Taiwan, Turkey (Türkiye), Ukraine, United Kingdom
- Top Cities: São Paulo, Seoul, Barcelona, Madrid, Shanghai

---

### NCT06955377: Effect of Forward Trunk Flexion in Patients With Parkinson's Disease on the Airway Defense System

**Status:**
- Overall Status: RECRUITING
- Start Date: 2025-02-18
- Completion Date: 2029-02

**Design:**
- Study Type: OBSERVATIONAL
- Phases: N/A
- Allocation: N/A
- Intervention Model: N/A
- Primary Purpose: N/A
- Masking: N/A

**Eligibility:**
- Sex: ALL
- Minimum Age: 18 Years
- Healthy Volunteers: false
- Age Groups: ADULT, OLDER_ADULT
- Criteria: Inclusion Criteria:

* Diagnosis of Parkinson' s disease
* Age ≥ 18 years

Exclusion Criteria:

* Unreliable performance of MIP, MEP, or grip strength measurements, for example, due to cognitive defic...

**Primary Outcomes:**
- Voluntary peak cough flow
  Time Frame: baseline, 12months, 24months, 36months
- Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP)
  Time Frame: baseline, 12months, 24months, 36months
- Forced vital capacity (FVC)
  Time Frame: baseline, 12months, 24months, 36months
- Forced expiratory volume (FEV1)
  Time Frame: baseline, 12months, 24months, 36months
- Peak expiratory flow (PEF)
  Time Frame: baseline, 12months, 24months, 36months

**Secondary Outcomes:**
- Hand grip strength
- Index of Pulmonary Dysfunction (IPD)

**Sponsors:**
- Lead: General University Hospital, Prague (OTHER)

**Locations:**
- Total: 1
- Countries: Czechia
- Top Cities: Prague
